(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
-2.76% HKD 12.00
Live Chart Being Loaded With Signals
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally...
Stats | |
---|---|
Tagesvolumen | 5.89M |
Durchschnittsvolumen | 12.27M |
Marktkapitalisierung | 25.22B |
EPS | HKD0 ( 2024-03-29 ) |
Nächstes Ertragsdatum | ( HKD0 ) 2024-05-17 |
Last Dividend | HKD0.0120 ( 2017-06-05 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -34.29 |
ATR14 | HKD0.0100 (0.08%) |
Volumen Korrelation
Genscript Biotech Corp Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Genscript Biotech Corp Korrelation - Währung/Rohstoff
Genscript Biotech Corp Finanzdaten
Annual | 2023 |
Umsatz: | HKD839.53M |
Bruttogewinn: | HKD409.55M (48.78 %) |
EPS: | HKD-0.0453 |
FY | 2023 |
Umsatz: | HKD839.53M |
Bruttogewinn: | HKD409.55M (48.78 %) |
EPS: | HKD-0.0453 |
FY | 2022 |
Umsatz: | HKD625.70M |
Bruttogewinn: | HKD304.08M (48.60 %) |
EPS: | HKD-0.110 |
FY | 2021 |
Umsatz: | HKD510.60M |
Bruttogewinn: | HKD303.02M (59.35 %) |
EPS: | HKD-0.171 |
Financial Reports:
No articles found.
Genscript Biotech Corp Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
First Dividend | HKD0.0120 | 2017-06-05 |
Last Dividend | HKD0.0120 | 2017-06-05 |
Next Dividend | HKD0 | N/A |
Payout Date | 2017-06-21 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | HKD0.0120 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.29 | -- |
Div. Sustainability Score | 2.51 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0.922 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6862.HK | Ex Dividend Junior | 2023-06-09 | Annually | 0 | 0.00% | |
1962.HK | Ex Dividend Junior | 2023-09-11 | Annually | 0 | 0.00% | |
0991.HK | Ex Dividend Junior | 2023-06-30 | Sporadic | 0 | 0.00% | |
0097.HK | Ex Dividend Junior | 2023-06-07 | Semi-Annually | 0 | 0.00% | |
3336.HK | Ex Dividend Junior | 2023-05-22 | Annually | 0 | 0.00% | |
1568.HK | Ex Dividend Junior | 2023-06-05 | Annually | 0 | 0.00% | |
0595.HK | Ex Dividend Junior | 2023-09-06 | Annually | 0 | 0.00% | |
9869.HK | Ex Dividend Junior | 2023-09-19 | Insufficient data to determine frequency | 0 | 0.00% | |
2130.HK | Ex Dividend Knight | 2023-06-16 | Semi-Annually | 0 | 0.00% | |
1126.HK | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.114 | 1.500 | -2.27 | -3.41 | [0 - 0.5] |
returnOnAssetsTTM | -0.0282 | 1.200 | -0.940 | -1.127 | [0 - 0.3] |
returnOnEquityTTM | -0.0695 | 1.500 | -1.884 | -2.83 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.76 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.34 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.92 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.123 | -1.500 | 7.95 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.144 | 2.00 | -0.0480 | -0.0959 | [0 - 30] |
freeCashFlowPerShareTTM | -0.271 | 2.00 | -0.135 | -0.271 | [0 - 20] |
debtEquityRatioTTM | 0.300 | -1.500 | 8.80 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.488 | 1.000 | 5.20 | 5.20 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.495 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.688 | 1.000 | -4.93 | -4.93 | [0.2 - 2] |
assetTurnoverTTM | 0.248 | 0.800 | -1.681 | -1.345 | [0.5 - 2] |
Total Score | 2.51 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -32.08 | 1.000 | -3.34 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0695 | 2.50 | -1.211 | -2.83 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.271 | 2.00 | -0.0902 | -0.271 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.144 | 2.00 | -0.0480 | -0.0959 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 2.27 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.342 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -0.665 |
Genscript Biotech Corp
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.